Spire Wealth Management’s Unity Biotechnology UBX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q2
Sell
-274
Closed -$17K 2965
2021
Q1
$17K Buy
+274
New +$18.7K ﹤0.01% 2224

Other funds holding UBX

Spire Wealth Management's UBX Position: Q2 2021 in Review

Spire Wealth Management sold out of Unity Biotechnology (UBX) in Q2 2021, closing a stake of 274 shares — an estimated $17K sold.

Spire Wealth Management first reported a position in UBX in Q1 2021 and held it in 1 quarter. The position peaked at $17K in Q1 2021. 98 funds tracked by Wall St. Rank hold UBX as of Q2 2021.

  • Spire Wealth Management reported no remaining Unity Biotechnology position as of Q2 2021 after selling out during the quarter.
  • Spire Wealth Management sold 274 Unity Biotechnology shares in Q2 2021, an estimated $17K.
  • Spire Wealth Management first reported a position in Unity Biotechnology in Q1 2021 and held it in 1 quarter.
  • Spire Wealth Management's Unity Biotechnology position peaked at $17K in Q1 2021.
  • 98 funds tracked by Wall St. Rank held Unity Biotechnology as of Q2 2021.

Based on Spire Wealth Management's 13F filing for Q2 2021, filed 26 Jul 2021.